Compare InMode Ltd (INMD) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs Invesco Ltd. — how do they compare? InMode Ltd trades at $15.25 (market cap $872.08M), while Invesco Ltd. trades at $31.45 (market cap $13.85B). The key difference: Invesco Ltd. is far larger — about 15.9× InMode Ltd's market cap, and Invesco Ltd. pays a 2.74% dividend while InMode Ltd pays none. Which is the better fit depends on your goals.
| INMD | IVZ | |
|---|---|---|
Market Cap | $872.08M | $13.85B |
Sector | Technology | Financials |
52-Week High | $16.62 | $32.01 |
52-Week Low | $12.76 | $20.67 |
Enterprise Value | $375.42M | $24.01B |
Dividend Yield | — | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INMD trades at $15.23, up 0.26% today, with a neutral technical outlook and mixed earnings history including a Q1 2026 miss. The company reported Q2 2026 revenue of $95.6 million, consistent year-over-year, and maintains a strong gross profit margin of 76.52%. Recent news highlights an unsolicited acquisition offer from Steel Partners at $16.75 per share and shareholder activism urging rejection, creating uncertainty around corporate governance.
The stock presents a value opportunity with low P/E and EV/EBITDA ratios, but risks include earnings volatility, potential acquisition fallout, and ongoing securities fraud investigations. Analyst consensus is divided between Buy and Hold ratings, reflecting cautious optimism amid near-term headwinds. Long-term growth depends on execution of international expansion and innovation in medical technologies.
Invesco (IVZ) trades at $31.58, down 0.5% today but near its 52-week high, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, with Q3 results pending. Revenue has grown to $6.38 billion in 2025, though net income remains negative. Analyst consensus is a $32.50 price target with a mix of Buy and Hold ratings, and the firm maintains a stable dividend payout.
The outlook for IVZ is cautiously optimistic, supported by strong assets under management and positive cash flow trends. However, profitability challenges and expense pressures pose risks. Upside potential hinges on earnings improvement and market sentiment, while downside risks include margin compression and competitive pressures in asset management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
